These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2286358)

  • 1. Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.
    Bell JB; Millar BC; Montes-Borinaga A; Joffe JK; Cunningham D; Mansi J; Treleaven J; Viner C; McElwain TJ
    Hematol Oncol; 1990; 8(6):347-53. PubMed ID: 2286358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myeloma.
    Millar BC; Bell JB; Maitland JA; Zuiable A; Gore ME; Selby PJ; McElwain TJ
    Br J Haematol; 1989 Feb; 71(2):213-22. PubMed ID: 2923807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.
    Maitland JA; Millar BC; Bell JB; Montes A; Treleaven J; Gore ME; McElwain TJ
    Br J Cancer; 1990 Mar; 61(3):429-33. PubMed ID: 2328211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma.
    Raje N; Powles R; Kulkarni S; Milan S; Middleton G; Singhal S; Mehta J; Millar B; Viner C; Raymond J; Treleaven J; Cunningham D; Gore M
    Br J Haematol; 1997 Apr; 97(1):153-60. PubMed ID: 9136958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in clonogenic tumour cells in bone marrow of patients with multiple myeloma treated with vincristine, doxorubicin, and methylprednisolone.
    Bell JB; Millar BC; Maitland JA; Nandi A; Gore M; McElwain TJ
    Lancet; 1988 Oct; 2(8617):931-3. PubMed ID: 2902382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.
    Forgeson GV; Selby P; Lakhani S; Zulian G; Viner C; Maitland J; McElwain TJ
    Br J Cancer; 1988 Oct; 58(4):469-73. PubMed ID: 3207601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
    McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6 is a cofactor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogenicity of myeloma cells in vitro.
    Borinaga AM; Millar BC; Bell JB; Joffe JK; Millar JL; Gooding R; Riches P; McElwain TJ
    Br J Haematol; 1990 Dec; 76(4):476-83. PubMed ID: 2265109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.
    Davies FE; Forsyth PD; Rawstron AC; Owen RG; Pratt G; Evans PA; Richards SJ; Drayson M; Smith GM; Selby PJ; Child JA; Morgan GJ
    Br J Haematol; 2001 Mar; 112(3):814-9. PubMed ID: 11260088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Hagiwara S; Miwa A
    Int J Hematol; 2018 May; 107(5):559-567. PubMed ID: 29388164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.
    Millar BC; Bell JB; Barfoot R; Everard M
    Br J Cancer; 1995 Feb; 71(2):259-64. PubMed ID: 7841038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy and autologous bone marrow transplantation for myeloma.
    McElwain TJ; Selby PJ; Gore ME; Viner C; Meldrum M; Millar BC; Malpas JS
    Eur J Haematol Suppl; 1989; 51():152-6. PubMed ID: 2697587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
    Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
    Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningeal myeloma in the absence of systemic disease, and as the initial feature of disease progression.
    Somers LJ; Shaw B; Lyn BE; McMillan AM; Mahendra P
    Clin Lab Haematol; 1998 Jun; 20(3):189-90. PubMed ID: 9681237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft.
    Sirohi B; Powles R; Rudin C; Singhal S; Kulkarni S; Saso R; Horton C; Mehta J; Treleaven J
    Hematology; 2005 Oct; 10(5):361-4. PubMed ID: 16203605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating combination chemotherapy does not delay development of refractoriness in myeloma.
    Osby E; Beksac M; Reizenstein P
    Anticancer Res; 1986; 6(5):1145-7. PubMed ID: 3800322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer.
    Taylor CW; Dalton WS; Mosley K; Dorr RT; Salmon SE
    Breast Cancer Res Treat; 1997 Jan; 42(1):7-14. PubMed ID: 9116320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VAD followed by VMCP: an alternative regimen for multiple myeloma.
    Wadhwa J; Kumar L; Kochupillai V
    Med Oncol; 2002; 19(2):105-8. PubMed ID: 12180477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.